Holen Sie sich die Stockscreener-App
6.26
0.97%
0.06
Schlusskurs vom Vortag:
$6.20
Offen:
$6.16
24-Stunden-Volumen:
346.11K
Relative Volume:
1.85
Marktkapitalisierung:
$295.68M
Einnahmen:
$31.37M
Nettoeinkommen (Verlust:
$-53.77M
KGV:
-4.3063
EPS:
-1.4537
Netto-Cashflow:
$-49.02M
1W Leistung:
-1.11%
1M Leistung:
-1.42%
6M Leistung:
+21.55%
1J Leistung:
-15.41%
1-Tages-Spanne:
$5.95
$6.30
1-Wochen-Bereich:
$5.95
$7.4258
52-Wochen-Spanne:
$1.97
$8.08
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Firmenname
Silence Therapeutics Plc Adr
Sektor
Branche
Telefon
44-0-20-3457 6900
Adresse
12 HAMMERSMITH GROVE, LONDON
Vergleichen Sie SLN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
6.26 | 292.85M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Goldman | Sell |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Aktie (SLN) Neueste Nachrichten
Does Silence Therapeutics Plc ADR (SLN) offer a good opportunity for investors? - Setenews
Saturn V Capital Management LP Lowers Position in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Silence Therapeutics Plc ADR (SLN) is looking forward to a strong quarter - Setenews
Net current asset value per share of Silence Therapeutics PLC Sponsored ADR – FWB:XRP2 - TradingView
HC Wainwright Has Bullish Forecast for SLN FY2025 Earnings - Defense World
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Barchart.com
Brokerages Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) PT at $32.60 - Defense World
SLN: Revenue fell, net loss widened, and cash will fund operations into 2028, but more funding needed - TradingView
Silence Therapeutics (SLN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Silence Therapeutics (NASDAQ:SLN) Stock Price Down 2.1%Time to Sell? - MarketBeat
5 Under-the-Radar Biotech Stocks That Could Soar in 2026 - Barchart.com
Silence Therapeutics completes enrollment in PV treatment study - Investing.com
Check Out Insider Trades For Silence Therapeutics Plc ADR (SLN) Stock - fostersleader.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Average Price Target from Analysts - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
GAMMA Investing LLC Buys 4,773 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Goldman Sachs Group Inc. Sells 12,510 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Consensus Target Price from Analysts - Defense World
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire Inc.
Silence Therapeutics (OTCMKTS:SLNCF) Shares Down 5% – Here’s What Happened - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Silence Therapeutics (SLN) Stock Price, News & Analysis - MarketBeat
Silence Therapeutics director Michael Davidson resigns from board - Investing.com
Silence Therapeutics director Michael Davidson resigns from board By Investing.com - Investing.com India
William Blair Issues Pessimistic Forecast for SLN Earnings - Defense World
Silence Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com South Africa
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $33.83 Average PT from Analysts - Defense World
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade - Yahoo.co
Stephens Inc. AR Invests $260,000 in Evergy Inc. (NASDAQ:EVRG) - Defense World
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Price Up 20.7% – Still a Buy? - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus - Nasdaq
Silence Therapeutics soars 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
H.C. Wainwright reiterates buy rating on Silence Therapeutics stock By Investing.com - Investing.com South Africa
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - MSN
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - Yahoo Finance
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - Nasdaq
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Nasdaq
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
Silence Therapeutics stock holds Buy rating on positive trial results By Investing.com - Investing.com UK
Silence Therapeutics director Alistair Gray retires - Investing.com
Zerlasiran shows promise in lowering cardiovascular risk - Investing.com
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Nasdaq
Silence Therapeutics to Join Guggenheim Biotech Conference By Investing.com - Investing.com South Africa
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy - Yahoo Finance
Finanzdaten der Silence Therapeutics Plc Adr-Aktie (SLN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):